Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274359 | 0.99 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3135002 | 0.88 | GSK3B (0.56) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL15135440 | 0.86 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3139329 | 0.84 | GSK3B (0.57) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3274357 | 0.84 | GSK3B (0.55) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3140732 | 0.83 | GSK3B (0.56) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL15135387 | 0.81 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL173216 | 0.76 | GSK3B (0.61) | GSK3BCYP2D6 | |
| SCHEMBL3154820 | 0.76 | GSK3B (0.49) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3274219 | 0.76 | GSK3B (0.49) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, HPRT1, XDH | GSK3B 3294/4885CYP2D6 78/4885CYP1A2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.